McKesson (NYSE:MCK) Releases FY 2025 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 32.400-33.000 for the period, compared to the consensus estimate of 31.990. The company issued revenue guidance of $355.3 billion-$361.5 billion, compared to the consensus revenue estimate of $351.8 billion.

Analysts Set New Price Targets

MCK has been the subject of several research analyst reports. Mizuho raised their price target on shares of McKesson from $540.00 to $570.00 and gave the stock a “neutral” rating in a research note on Thursday, August 8th. Baird R W raised McKesson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Citigroup upped their price target on McKesson from $630.00 to $713.00 and gave the company a “buy” rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft decreased their price objective on McKesson from $623.00 to $579.00 and set a “buy” rating for the company in a report on Wednesday, September 25th. Finally, Barclays increased their target price on shares of McKesson from $596.00 to $616.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $631.57.

McKesson Stock Performance

MCK stock opened at $610.03 on Friday. The firm has a market cap of $77.44 billion, a P/E ratio of 31.59, a P/E/G ratio of 1.35 and a beta of 0.44. The firm’s fifty day moving average is $516.06 and its 200 day moving average is $553.41. McKesson has a 52 week low of $431.35 and a 52 week high of $637.51.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.88 by $0.19. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The firm had revenue of $93.65 billion for the quarter, compared to analysts’ expectations of $89.33 billion. During the same quarter last year, the business earned $6.23 earnings per share. The business’s revenue was up 21.3% on a year-over-year basis. As a group, analysts forecast that McKesson will post 32.81 EPS for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Monday, December 2nd. McKesson’s payout ratio is 14.71%.

Insiders Place Their Bets

In other news, CEO Brian S. Tyler sold 3,753 shares of McKesson stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $561.10, for a total value of $2,105,808.30. Following the completion of the transaction, the chief executive officer now owns 78,586 shares of the company’s stock, valued at $44,094,604.60. The trade was a 4.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.11% of the stock is owned by corporate insiders.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.